RESOURCES

The resources here are intended for healthcare professionals who would like to find out more about APDS. They cover a range of topics on APDS from the clinical manifestations, to disease burden and current treatment options. These resources have been developed in partnership with experts in the field, who have first-hand experience with APDS patients. To view each resource, simply click on the topic of interest.

What is APDS

Dr Virgil Dalm, consultant immunologist from Erasmus MC, Rotterdam, The Netherlands, explains what APDS is.

What are the most common features of APDS

Dr Anita Chandra, consultant immunologist from Cambridge University Hospitals and the University of Cambridge, UK, explains the most common features of APDS.

How is APDS diagnosed

Dr Anita Chandra, consultant immunologist from Cambridge University Hospitals and the University of Cambridge, UK, explains how APDS is diagnosed.

How long does it take to get a diagnosis of APDS

Dr Virgil Dalm, consultant immunologist from Erasmus MC, Rotterdam, The Netherlands, explains about getting an APDS diagnosis.

What is genetic testing

Dr Virgil Dalm, consultant immunologist from Erasmus MC, Rotterdam, The Netherlands, explains what genetic testing is.

What are the current treatment & management options

Dr Anita Chandra, consultant immunologist from Cambridge University Hospitals and the University of Cambridge, explains the current treatment and management options for APDS.

What is it like living with APDS

Dr Virgil Dalm, consultant immunologist from Erasmus MC, Rotterdam, The Netherlands, explains what living with APDS is like.

More resources will be added in the future, so please remember to revisit this page periodically.

Image shows the cover of the IPOPI APDS Booklet

Download the IPOPI information booklet about APDS.

IPOPI – International Patient Organisation for Primary Immunodeficiencies, is an independent, non-profit international organisation and the leading advocate for primary immunodeficiency (PID) patients worldwide working in collaboration with patients, doctors, politicians, regulators, pharmaceutical industry and other relevant stakeholders. This document has been developed by IPOPI in conjunction with Novartis and Pharming.